The potential of exosomes as an alternative delivery vector for the CRISPR/Cas9 components encourages Creative Biolabs to present its exosome engineering strategies.

Considering a recently featured article by NIH introducing the therapeutic effects of NSC-derived exosomes in cerebral ischemia, Creative Biolabs updates its service portfolio related to stem cell-derived exosomes.

Creative Biolabs, a leading life science company specialized in exosome research services, has been one of the top players of growing exosome market size and trend based on its full-scale exosome sampling, analysis, and manufacturing services.

To better aid SARS-CoV-2 drug discovery, Creative Biolabs updates its exosome services for displaying ACE2 variants on the surface of small extracellular vesicles.